Actome

Executive Summary

Actome (PICO BioScience) is a Berlin-based biotechnology company founded in 2018 that has developed the proprietary Protein Interaction Coupling (PICO) technology, a digital PCR-based immunoassay platform enabling absolute, reference-free quantification of proteins, protein interactions, post-translational modifications, and extracellular vesicles. This technology offers unprecedented sensitivity and precision for proteomic analysis, addressing critical needs in biomarker discovery, drug development, and diagnostics. Actome commercializes its platform through kits, services, and software, targeting both academic and industrial researchers. The company's approach could democratize access to high-quality proteomic data, potentially disrupting traditional mass spectrometry-based methods. Despite being privately held with no disclosed funding or stage, Actome's innovative platform positions it well in the rapidly growing proteomics market, projected to exceed $5 billion by 2030. The company's focus on absolute quantification and compatibility with standard PCR infrastructure lowers barriers to adoption. Near-term catalysts include product launches expanding its assay menu, strategic collaborations with pharmaceutical partners, and a likely Series A funding round to accelerate commercial growth. If successful, Actome could become a key player in the proteomics tools space, though execution risks and competitive pressure from established players remain.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of new PICO assay kits for oncology biomarkers70% success
• Q4 2026Strategic partnership with a major pharmaceutical company for proteomic services60% success
• 2027Series A financing round to scale operations and expand market reach80% success